PE20100154A1 - Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen - Google Patents

Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen

Info

Publication number
PE20100154A1
PE20100154A1 PE2009000762A PE2009000762A PE20100154A1 PE 20100154 A1 PE20100154 A1 PE 20100154A1 PE 2009000762 A PE2009000762 A PE 2009000762A PE 2009000762 A PE2009000762 A PE 2009000762A PE 20100154 A1 PE20100154 A1 PE 20100154A1
Authority
PE
Peru
Prior art keywords
beta
pregn
carbolactones
substituted
contain
Prior art date
Application number
PE2009000762A
Other languages
English (en)
Inventor
Sven Ring
Rolf Bohlmann
Joachim Kuhnke
Ludwig Zorn
Steffen Borden
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41061273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20100154A1 publication Critical patent/PE20100154A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PREGN-4-EN-21,17-CARBOLACTONAS DE FORMULA (I), DONDE R6,7 ES METILENO EN POSICION ALFA O BETA; R9 ES H; R11 ES Br, Cl, F; R9 Y R11 JUNTOS FORMAN UN ENLACE. SON COMPUESTOS SELECCIONADOS 6(BETA),7(BETA);15(BETA),16(BETA)-DIMETILEN-3-OXO-17-PREGNA-4,9(11)-DIEN-21,17(BETA)-CARBOLACTONA; 11(BETA)-CLORO-6(BETA),7(BETA);15(BETA),16(BETA)-DIMETILEN-3-OXO-17-PREGN-4-EN-21,17(BETA)-CARBOLACTONA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGENTES UTLES PARA EL TRATAMIENTO DE TRASTORNOS PREMENSTRUALES TALES COMO CEFALEAS, HUMOR DEPRESIVO, RETENCION DE AGUA, MASTODINIA, ENTRE OTROS
PE2009000762A 2008-06-02 2009-06-02 Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen PE20100154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008026793A DE102008026793A1 (de) 2008-06-02 2008-06-02 C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
PE20100154A1 true PE20100154A1 (es) 2010-03-20

Family

ID=41061273

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000762A PE20100154A1 (es) 2008-06-02 2009-06-02 Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen

Country Status (29)

Country Link
US (1) US20110130371A1 (es)
EP (1) EP2297177B1 (es)
JP (1) JP2012528075A (es)
KR (1) KR20110020240A (es)
CN (1) CN102046646B (es)
AR (1) AR071984A1 (es)
AU (1) AU2009254266A1 (es)
BR (1) BRPI0913401A2 (es)
CA (1) CA2726855A1 (es)
CL (1) CL2009001342A1 (es)
CO (1) CO6321132A2 (es)
CR (1) CR11821A (es)
DE (1) DE102008026793A1 (es)
DO (1) DOP2010000372A (es)
EA (1) EA017570B1 (es)
EC (1) ECSP10010652A (es)
ES (1) ES2389237T3 (es)
HK (1) HK1156954A1 (es)
HN (1) HN2010002548A (es)
IL (1) IL209371A0 (es)
MA (1) MA32321B1 (es)
MX (1) MX2010013233A (es)
NZ (1) NZ589593A (es)
PE (1) PE20100154A1 (es)
SV (1) SV2010003748A (es)
TW (1) TW201000106A (es)
UY (1) UY31859A (es)
WO (1) WO2009146811A1 (es)
ZA (1) ZA201009097B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004248A1 (de) 2010-07-08 2012-01-12 Bayer Pharma Aktiengesellschaft MIKROBIOLOGISCHES VERFAHREN ZUR HERSTELLUNG VON 11α-HYDROXY-DROSPIRENON
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
CN102876582B (zh) * 2011-07-15 2015-01-07 复旦大学 金龟子绿僵菌突变株及其在甾体化合物羟化反应中的应用
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
CN105779553B (zh) * 2014-12-15 2020-10-27 天津金耀集团有限公司 新月弯孢霉和节杆菌联合发酵制备11β-羟基-1,4-二烯-3,20-二酮甾体化合物
CN105779555B (zh) * 2014-12-15 2021-02-02 天津金耀集团有限公司 犁头霉和节杆菌联合发酵制备11β-羟基-1,4-二烯-3,20-二酮甾体化合物
CN104862323B (zh) * 2015-06-02 2018-01-16 中国农业科学院生物技术研究所 修饰苯二酚类化合物的羟化酶基因

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3092628A (en) * 1959-05-29 1963-06-04 Merck & Co Inc Aldosterone antagonists
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3539558A (en) * 1968-08-09 1970-11-10 Searle & Co 3 - oxygenated 3 - (9alpha,11beta - dichloro-17beta- hydroxyandrosten - 17alpha-yl)propionic acid gamma-lactones and congeners
DE2453823C2 (de) * 1974-11-11 1984-08-09 Schering AG, 1000 Berlin und 4709 Bergkamen 11β,17α-Dihydroxy-15α,16α-methylen-1,4-pregnadien-3,20-dion
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
HUP0402466A2 (en) * 2004-11-30 2006-07-28 Richter Gedeon Vegyeszet Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
ATE403668T1 (de) * 2005-07-21 2008-08-15 Bayer Schering Pharma Ag Verfahren zur herstellung von 3-oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie oxidation von 17-(3-hydroxypropyl)-3,17- dihydroxyandrostanen
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
DE102006030416A1 (de) 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
ITMI20061802A1 (it) * 2006-09-22 2008-03-23 Antibioticos Spa Epossidazione di 17-oxo-15,16-metilen steroidi con ilidi di solfossonio

Also Published As

Publication number Publication date
HK1156954A1 (es) 2012-06-22
AR071984A1 (es) 2010-07-28
CL2009001342A1 (es) 2010-05-28
HN2010002548A (es) 2012-08-27
MA32321B1 (fr) 2011-05-02
CA2726855A1 (en) 2009-12-10
CR11821A (es) 2011-02-04
US20110130371A1 (en) 2011-06-02
CN102046646B (zh) 2013-03-27
EA017570B1 (ru) 2013-01-30
TW201000106A (en) 2010-01-01
SV2010003748A (es) 2011-04-06
CN102046646A (zh) 2011-05-04
EP2297177A1 (de) 2011-03-23
CO6321132A2 (es) 2011-09-20
AU2009254266A1 (en) 2009-12-10
UY31859A (es) 2010-01-05
MX2010013233A (es) 2010-12-21
DE102008026793A1 (de) 2009-12-03
JP2012528075A (ja) 2012-11-12
WO2009146811A1 (de) 2009-12-10
IL209371A0 (en) 2011-01-31
BRPI0913401A2 (pt) 2015-11-24
KR20110020240A (ko) 2011-03-02
ECSP10010652A (es) 2011-01-31
EA201001861A1 (ru) 2011-08-30
ZA201009097B (en) 2012-05-01
NZ589593A (en) 2012-04-27
ES2389237T3 (es) 2012-10-24
EP2297177B1 (de) 2012-06-20
DOP2010000372A (es) 2010-12-31

Similar Documents

Publication Publication Date Title
PE20100154A1 (es) Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
CO2017011411A2 (es) Derivados de ciclohexano sustituido con amido
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR8531A (es) Compuestos y procedimientos para su uso
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
CR7876A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
CR8636A (es) Compuestos utiles para el tratamiento de enfermedades
BR112015004523A2 (pt) compostos de tetraciclina
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
CL2011000865A1 (es) Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras.
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
EA201791321A1 (ru) Составы ингибитора lfa-1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed